Bavarian Nordic Donates Mpox Vaccine to Global Stockpile
The pharmaceutical company is donating 75,000 doses to help improve equitable access to the MVA-BN vaccine during outbreaks.
Updated on Oct. 27, 2026 in COVID-19
Live Poll
Do you trust pharmaceutical partnerships to adequately secure and distribute vaccines for future global health emergencies?
Bavarian Nordic announced a donation of 75,000 doses of its MVA-BN vaccine to a new global emergency stockpile. The company also secured a contract to supply an additional 150,000 doses to ensure that emergency supplies remain available for international response.
Why it matters
The new global stockpile, managed by the International Coordinating Group, is designed to provide timely and equitable access to vaccines for countries facing mpox outbreaks. Providing these doses supports the global health mission to stabilize immunization efforts in vulnerable areas.
Bavarian Nordic is providing 75,000 donated doses alongside 150,000 contracted units to the stockpile. The MVA-BN vaccine is authorized for use in individuals aged 12 and older via WHO prequalification, with EU approval covering children as young as 2.
The players
Bavarian Nordic
This biotechnology company is headquartered in Copenhagen, Denmark, and specializes in the research and manufacture of vaccines for infectious diseases.
International Coordinating Group
This entity manages the allocation and deployment of emergency vaccine supplies to countries responding to global disease outbreaks.
Gavi, the Vaccine Alliance
This global health partnership provides funding and support to improve access to new and underused vaccines for children living in the world's poorest countries.
The details
Gavi, the Vaccine Alliance, provided the initial funding for the emergency stockpile that will now house the MVA-BN vaccine. This non-replicating vaccine is currently approved for use in several jurisdictions, including the United States, Singapore, and the European Union.
Timeline
2022-2024: Bavarian Nordic supported mpox vaccine access in 70 countries.
2024: MVA-BN vaccine received WHO prequalification.
October 27, 2026: Bavarian Nordic announced the vaccine donation and supply contract.
Health Landscape
This effort aligns with the operational framework of the International Coordinating Group on Vaccine Provision to centralize emergency medical resources. It represents a coordinated shift toward maintaining pre-positioned global supply caches to replace reactive, country-by-country procurement.
This initiative ensures that more regions have rapid access to authorized mpox vaccines when an outbreak occurs, potentially limiting the spread of the virus. For medical providers, the expansion of age-based authorizations allows for more flexible treatment protocols in pediatric populations.
The takeaway
Maintaining an emergency stockpile helps prevent the scramble for limited supplies during the onset of an outbreak. Establishing these reserves allows health authorities to deploy preventative measures more efficiently across borders.
Further reading
For more information on current global disease prevention efforts, visit the COVID-19 section.
More information
Find further corporate and product details on the Bavarian Nordic company information portal.
Live Poll
Do you trust pharmaceutical partnerships to adequately secure and distribute vaccines for future global health emergencies?
